Eli Lilly and Company

American Monitor Corporation

Eli Lilly Company

Thomas Wesley Stephens

Mark Louis Heiman

Juliana Maude Bue-Valleskey

Frank C Tinsley

Jose F Caro

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods of treating neuropeptide Y-associated conditions

This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

Methods of treating nueropeptide Y-associated conditions

This invention provides a method for optimizing the administration of leptin receptor ligands to a mammal in need of such treatment. More specifically, this invention provides an improved method of delivering leptin receptor ligands to a mammal in need of such treatment comprising pulsatile or peak delivery of leptin receptor ligands to treat obesity and related conditions, including hyperglucocorticoidinemia, fertility or delayed puberty, and/or growth hormone deficiencies.

Pulsatile delivery of leptin receptor ligands

This invention describes methods of treating or preventing diabetes in obese type II diabetic patients. Specifically, methods of treating obese type II diabetics with varying levels of endogenous circulating leptin are claimed.

Methods for treating diabetes

An improved colorimetric assay method and reagent composition for the quantitative determination of creatinine in biological fluid specimens in the presence of protein, in which the specimen is reacted directly with an alkaline picrate reagent composition which contains an iron chelator, preferably ethylenediaminetetraacetic acid, thereby significantly suppressing interference from bilirubin and improving reagent stability.

Assay for the determination of creatinine

A colorimetric assay method and reagent composition for the direct, quantitative determination of chloride in fluids which may be performed directly on non-deproteinized samples and which utilizes a reagent comprised of 2,4,6-tripyridyl-s-triazine, mercuric ions, ferrous ions, and a sulfate salt in a sulfate or sulfonate buffer at a selected pH in the range of about 1.5 to 3.0.

Growing community of inventors

Indianapolis, IN, United States of America

Thomas Wesley Stephens